Cowen & Co. Keeps a Buy Rating on SAGE Therapeutics (SAGE)

By Carrie Williams

Cowen & Co. analyst Ritu Baral maintained a Buy rating on SAGE Therapeutics (SAGEResearch Report) today and set a price target of $96.00. The company’s shares closed last Monday at $61.02, close to its 52-week low of $56.50.

According to, Baral is a top 100 analyst with an average return of 25.0% and a 52.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAGE Therapeutics with a $203.45 average price target, which is a 259.3% upside from current levels. In a report issued on November 20, Stifel Nicolaus also reiterated a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on SAGE Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $180 million. In comparison, last year the company had a GAAP net loss of $123 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.